Carter, A.J., & Nguyen, C.N. (2012). A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 12, 526 https://doi.org/10.1186/1471-2458-12-526
University Hospital. (2023, August 15). Benchtop to Bedside | A Conversation with Dr. Gary Schwartz, the New Leader of the Case Comprehensive Cancer Center. https://www.uhhospitals.org:443/for-clinicians/articles-and-news/articles/2023/08/a-conversation-with-dr-gary-schwartz-the-new-leader-of-the-case-comprehensive-cancer-center
Marks, J.L. (2022, September 6). Cancer Risks, Signs, Symptoms, Tests, Treatments, and More. Everyday Health. https://www.everydayhealth.com/cancer/guide/
Vivekanandhan, S., Bahr, D., & Kothari, A. et al. (2023). Immunotherapies in rare cancers. Mol Cancer 22, 23. https://doi.org/10.1186/s12943-023-01720-2
Alvi, M., Wilson, R., & Salto-Tellez, M. (2017). Rare cancers: the greatest inequality in cancer research and oncology treatment. Br J Cancer 117, 1255–1257. https://doi.org/10.1038/bjc.2017.321
Oberg, J.A., Ruiz, J., Ali-Shaw, T., Schlechtweg, K.A., Ricci, A., Kung, A.L., Chung, W. K., Appelbaum, P.S., Glade Bender, J.L., & Levine, J.M. Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. JCO Precision Oncology :2, 1-11 (2018). https://ascopubs.org/doi/full/10.1200/PO.17.00104?role=tab
Ortiz, M.V., Koenig, C., Armstrong, A., Brok, J., de Camargo, B., Mavinkurve-Groothuis, A.M.C., Velasquez Herrera, T.B., Venkatramani, R, Woods, A.D., Dome, J.S., & Spreafico, F. (2023). Advances in the clinical management of high-risk Wilms tumors. Pediatric Blood & Cancer 70(10) e30153 View Source
Cleveland Clinic Consult QD. (n.d.). Disparities Found in Funding of Cancer Research: Cancers that predominantly affect Black patients and cancers with higher mortality rates receive less funding. Cleveland Clinic. https://consultqd.clevelandclinic.org/disparities-found-in-funding-of-cancer-research/
Navin, N.E. (2015). The first five years of single-cell cancer genomics and beyond. Genome Research CHH Press. 25:1499-1507. https://genome.cshlp.org/content/25/10/1499.full?sid=7db3263e-b9df-4986-9af9-658952eac2ff
World Economic Forum. (2022, May 5). 8 new breakthroughs in the fight against cancer. https://www.weforum.org/agenda/2023/08/cancer-treatment-and-diagnosis-breakthroughs/
Association for Clinical Oncology. (n.d.), Federally Funded Cancer Research. https://old-prod.asco.org/get-involved/advocacy/advocacy-agenda-initiatives/federally-funded-cancer-research
Your generous donation is an investment in ending rare cancer as we know it.
We accelerate discovery
Comment, Like, Share & Follow Us on Social Media.
Together, we can take action against rare cancer and help save lives.
The Jed Ian Taxel Foundation for Rare Cancer Research | P.O. Box 683501 Park City, Utah 84068
The Jed Ian Taxel Foundation for Rare Cancer Research, Inc. is a 501 (C)(3) Non-Profit Organization, accepting Tax Deductible donations from individuals, corporations, family-advised funds and foundations. Federal Tax ID 86-2610819
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.